Literature DB >> 9930319

Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo.

M Ständer1, U Naumann, L Dumitrescu, M Heneka, P Löschmann, E Gulbins, J Dichgans, M Weller.   

Abstract

Cytokines such as transforming growth factor-beta (TGF-beta) are thought to mediate escape from immune surveillance in human malignant glioma. Here, we report that ectopic expression of the small TGF-beta-binding proteoglycan, decorin, inhibits not only TGF-beta bioactivity but also TGF-beta 1 and TGF-beta 2 mRNA transcription and TGF-beta protein synthesis by human LN-18, LN-229, T98G and rat C6 glioma cells in vitro. Ectopic expression of decorin in C6 rat glioma cells results in strong inhibition of tumor formation in vivo. Decorin-expressing C6 gliomas grow initially but regress to very small residual tumors at 12 weeks after implantation whereas all control animals die or have to be killed within 4 weeks. Decorin-expressing tumors show a four-fold increase of infiltration by activated T cells and a 1.6-fold increase in total B and T cells. Chronic steroid-mediated immunosuppression abrogates the inhibitory effects of decorin gene transfer. We conclude that decorin-induced inhibition of TGF-beta release by glioma cells significantly enhances antiglioma immune responses in vivo. Clinical evaluation of decorin gene therapy for human malignant gliomas may be warranted.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9930319     DOI: 10.1038/sj.gt.3300709

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  33 in total

1.  Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions.

Authors:  H Bouterfa; A R Darlapp; E Klein; T Pietsch; K Roosen; J C Tonn
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

Review 2.  TGF-beta antagonists: why suppress a tumor suppressor?

Authors:  Rosemary J Akhurst
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 3.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 4.  Pivotal role for decorin in angiogenesis.

Authors:  Hannu Järveläinen; Annele Sainio; Thomas N Wight
Journal:  Matrix Biol       Date:  2015-02-07       Impact factor: 11.583

Review 5.  Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.

Authors:  Slawomir Wojtowicz-Praga
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

Review 6.  Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta.

Authors:  W Wick; M Platten; M Weller
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

Review 7.  Medical applications of transforming growth factor-beta.

Authors:  Kathleen C Flanders; James K Burmester
Journal:  Clin Med Res       Date:  2003-01

Review 8.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

9.  Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model.

Authors:  Alireza Biglari; Dominique Bataille; Ulrike Naumann; Michael Weller; Jeffrey Zirger; Maria G Castro; Pedro R Lowenstein
Journal:  Cancer Gene Ther       Date:  2004-11       Impact factor: 5.987

10.  An antimetastatic role for decorin in breast cancer.

Authors:  Silvia Goldoni; Daniela G Seidler; Jack Heath; Matteo Fassan; Raffaele Baffa; Mathew L Thakur; Rick T Owens; David J McQuillan; Renato V Iozzo
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.